Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic...
Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announce...
businesswire.com